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Abstract
This multidisciplinary study was undertaken to record the variation in gene and protein expression in a large cohort of patients with well defined clinical phenotypes. The patients, whose ages ranged from 4 years to 66 years, spanned a wide range of disease severity. They represented the first 100 patients who had been examined in Newcastle, had undergone a muscle biopsy, and provided a blood sample for DNA analysis. The study had three aims: to observe any trends in the analyses across the clinical groups, to correlate gene and protein expression in individual patients, and to use the data collected to assess the relative usefulness of different techniques in the diagnosis and prognosis of patients with Duchenne and Becker dystrophy (DMD/BMD). In part 1, we describe the clinical assessment of the patients and the trends that were observed across the cohort. The patients were divided into seven groups. Group 1 had severe DMD (n = 21), group 2 had milder DMD (n = 20), group 3 were intermediate D/BMD patients (n = 9), group 4 had severe BMD (n = 5), and group 5 were more typical BMD patients (n = 31). Some patients were too young to be classified (n= 7) and a group of all the female patients were also classified separately (n = 7). The number of DMD and BMD patients was about equal, in accord with disease prevalence in the north of England, but an unusually high proportion were sporadic cases. Dystrophin labelling (performed with up to three antibodies) on both blots and sections increased gradually across the clinical groups. All histopathological indices, except the proportion of fat in biopsy sections, showed clear trends across the groups. (J Med Genet 1993;30:728-36) Duchenne and Becker muscular dystrophy (DMD, BMD) are both caused by defects in a gene on the X chromosome located at Xp21.12
The defects cause abnormal expression of the protein product, dystrophin, apparently in all patients."4 Most intragenic mutations are deletions, but duplications and point mutations have also been identified." The clinical spectrum of Xp2l linked muscular dystrophy varies from severe DMD, where the progressive loss of muscle function results in wheelchair dependency from about 7 years and death before 20 years, to mild BMD where a wheelchair may never be needed and a normal life span is frequently attained. In order to understand the pathogenesis of Duchenne and Becker dystrophy, the extent of variation in genotype and phenotype expression needs to be recorded. To this end we have undertaken a multidisciplinary investigation with the following three aims: to identify any patterns or trends in the analyses which would be shown by investigating a cohort of patients with a wide range of disease severity, to relate gene and protein defects in individual patients with well defined clinical phenotypes, and to identify which techniques are the most important for differential diagnosis and prognosis. The whole report has been divided into three sections, each addressing one of the aims defined above. In this first part we define the patient groups and report the pattern of results obtained across the clinical spectrum.
Materials and methods

PATIENT SELECTION
The 100 patients (93 male and seven female) included in this study were the first 100 patients with confirmed Xp2l linked muscular dystrophy who fulfilled the selection criteria of (1) having been examined at the Regional Neurosciences Centre of Newcastle General Hospital, (2) having undergone a muscle biopsy (which was stored in a liquid nitrogen archive), and (3) having provided a blood sample for lymphocyte DNA analysis. A further requirement was that, as far as possible, the patients were not related. Nevertheless, the 100 patients represent 98 family lines: also included were a nephew and uncle from one severe BMD family (patients F58 and F59 in the appendix) and a BMD father and his obligate carrier daughter (patients F67 and F94). The results from the genetic analysis were not known when the patient cohort was assembled but simple screening for dystrophin with a single antibody had been performed to confirm the initial clinical diagnosis.
CLINICAL ASSESSMENT
All patients in this study were examined by the same clinicians (DGM/KMDB). The following were recorded for each patient as appropriate: family history, age first walked, first symptoms, age first symptoms were observed, age at diagnosis, initial diagnosis, age at biopsy, age when ability to walk independently was lost, length of time in callipers (if used) before becoming wheelchair bound, length of time in wheelchair before death, age at death, IQ, age first words spoken, age first sentences constructed, achievements at school, further education, and employment undertaken. During the early years the times taken to run along a standard 11 m length of corridor, to climb six stairs, and to get up from the floor were recorded at every hospital visit. Measurements of forced vital capacity were also made at intervals following the loss of independent mobility. The disability of Becker patients was assessed according to the Cornelio scale. 89 The strength of all the major muscle groups was tested and the results were related to age, a low score indicating little reduction in muscle function. Electrophysiological studies (EMG/ECG) had been performed on too few patients in this cohort for inclusion.
PATIENT CLASSIFICATION
The patients were basically classified according to the standard clinical criterion of the age at which independent mobility was lost and full length callipers or a wheelchair had to be used. Thus DMD patients lost the ability to walk independently by 12 years of age, intermediate D/BMD patients between 12 and 16 years, and BMD patients could walk independently until they were at least 16 years old. For the purposes of comparison in this investigation, however, the number of clinical groups was expanded. Among our entire population of DMD patients (not just those in this study) the average age of becoming wheelchair bound is just over 9 years. We therefore divided the DMD patients in this study into two groups: those in a wheelchair before 9 years (group 1, n = 21) and those who lost mobility between 91 and 12 years of age (group 2, n=20). Patients with intermediate clinical symptoms (wheelchair bound 12 1 to 16 years) formed group 3 (n = 9). The BMD patients were also divided into two groups: those in a wheelchair between 16 and 40 years (group 4, n =5) and those not in a wheelchair until past 40, if at all (group 5, n= 31). Patients who were still ambulatory were assigned to clinical groups according to muscle function tests: group 4 patients corresponding to the 'severe Becker' group and group 5 to the 'typical Becker' group differentiated on the basis of Cornelio muscle function analysis described in detail by Bushby and Gardner-Medwin in 1993. 9 The females were considered together as a separate group (group F, n = 7). One (patient S95 in the appendix) was the single affected member of a pair of monozygous twins.'0
The current age range in our cohort of patients is from 4 to 66 years. Some of these patients could still walk independently. For the purposes of this study, most of these patients could be assigned to a clinical group according to their rate of disease progression. Detailed records are kept of every visit to the Regional Neurosciences Centre made by patients with muscular dystrophy so that a very large data base has been generated over the last 30 years. Thus it was possible to plot, for example, the time taken at different ages to run along an 11 m corridor or to get up from the floor for a very large number of patients in whom the whole clinical course had subsequently been recorded. By comparing the early data on patients whose clinical course was known with data collected on young patients who had not yet lost independent mobility, most young patients could be assigned to one of the five clinical groups. Nevertheless, patients under 6 years of age were still considered too young for assignment (group TY, n= 7) and we readily acknowledge that it is not possible to predict a clinical course from early observations with complete accuracy. It must also be emphasised that patients with Xp2l linked muscular dystrophy present a continuous, though not evenly distributed, spectrum of disease severity and separation into five clinical groups was undertaken purely for comparative purposes in this study. The criteria used have no implications for classification for diagnostic purposes.
GENETIC ANALYSIS
Analysis of DNA isolated from lymphocytes and digested with the restriction enzyme HindIII was performed using dystrophin cDNA probes 1-2a, 2b-3, 4-5a, 5b-7, 8, 9-10, and 11-14' according to established techniques.61' In some instances PCR analysis was performed using multiplex primers.'2 The genetic analysis for 50 patients was performed in Leiden, The Netherlands. Deletions and duplications could be detected but not point mutations or other very small genetic rearrangements. X chromosome inactivation studies were undertaken for the female patients using differential methylation and fluorescent in situ hybridisation techniques which have been described in detail previously.'013 ANTIBODIES USED FOR PROTEIN ANALYSIS Four monoclonal antibodies (MAbs) were used during this study: three to dystrophin and one to 3-spectrin. The rod and C-terminal dystrophin MAbs detect epitopes on either side of the major deletion 'hotspot'. Generation and use of the rod domain MAb, Dy4/ 6D3 (DYS 1), has been described previously. ' fig 2) . Dystrophin labelling among the female patients was very variable but all had some negative fibres, which were found in groups in some cases (S95, S98, and S99). The remaining fibres either showed a continuous spectrum of labelling from near normal to near negative (a pattern found in the younger patients F94, S96, and S97), or there was a high percentage of fibres with normal labelling (60 to 85%) with smaller proportions of fibres with decreased (10 to 20%) dystrophin labelling (patterns found in the older and more mildly affected patients, S98, S99, and S100).
BLOTTING
As with the labelling on sections, the abundance of dystrophin labelling on blots gradually increased as the clinical condition improved from group 1 to group 5 ( fig 3) . Analysis of variance for all five groups indicates that there is a significant difference (p < 0 001) and signi- Numbers in parentheses indicate the number of subjects with the same mutation. Deletions marked with * are known to maintain the reading frame. J= junctional fragment (deletion breakpoint close to, or in, an adjacent exon). ficant differences were also found when any two individual groups were compared (p < 0-05 in all comparisons except that for groups 1 + 2 which was not significant). The appendix summarises the estimates of dystrophin abundance and size for all patients, and blots illustrating the dystrophin labelling in individual patients can be seen in part 2 of this investigation. In every case, we have only considered the largest size polypeptide detected in each patient sample lane. One important difference between dystrophin labelling on blots and tissue sections was observed: while labelling on sections with the rod and C-terminal antibodies was virtually identical, labelling on blots was always less intense when the C-terminal MAb was used, which meant that labelling with the rod MAb had to be above a certain threshold before Cterminal labelling was detectable (fig 4) . All estimates of dystrophin abundance were lower with the C-terminal MAb. Table 2 indicates this difference in 72 male patients (insufficient muscle was available from some patients to produce blots for labelling with more than one 
